Figure 2From: Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile? Overall survival (OS) based on response to systemic therapy at the time of surgery, calculated from date of surgery. Back to article page